The November issue of Squire Patton Boggs Bio/Pharma Beat is now available. Our monthly newsletter reports on important patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from October 2019, including:

  • The Federal Circuit holds the “hope” that a potentially promising drug will treat a particular cancer is not enough to establish a reasonable expectation of success
  • The Federal Circuit holds a method of treating hepatitis C with a genus of compounds invalid for lack of enablement and written description
  • California enacts a “pay for delay” law